• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
PER
Click for more information
5.00% 7.6¢

PERCHERON THERAPEUTICS LIMITED - Charts / Financials

Market Cap $68.51M  ! watchlist Created with Sketch. Add to my watchlist
Healthcare

Percheron Therapeutics Limited, formerly Antisense Therapeutics Limited, is a... Percheron Therapeutics Limited, formerly Antisense Therapeutics Limited, is a biotechnology company. The Company is engaged in developing and commercializing antisense pharmaceuticals for large unmet markets in rare diseases. The Company’s products include ATL1102 for Duchenne muscular dystrophy (DMD), ATL1103 for Acromegaly, and ATL1102 for Multiple Sclerosis (MS). ATL1102, is an antisense inhibitor targeting very late antigen 4 (VLA-4), an immune cell molecule. ATL1103 is a second-generation antisense drug designed to block growth hormone receptor (GHr) expression thereby reducing levels of the hormone insulin-like growth factor-I (IGF-I) in the blood and is a potential treatment for diseases associated with excessive growth hormone action. By inhibiting GHr production, ATL1103 in turn reduces IGF-I levels in the blood (serum). The Company is conducting a Phase II clinical trial of ATL1102 in DMD patients.More

refresh Created with Sketch. REFRESH
Last update - 15.57pm 09/05/2024 (20 minute delay) ?
Day
Open 8.0¢   Day High 8.0¢   Day Low 7.6¢
Daily Volume 2545344
Bids   Sellers
Number Price Volume   Number Price Volume
2 7.6¢ 146314   2 8.3¢ 106165

Data source: Refinitiv

(20min delay)
Last
7.6¢ 		Change
-0.004(5.00%) 		Mkt cap ! $68.51M
Open High Low Value Volume
8.0¢ 8.0¢ 7.6¢ $201.6K 2.545M

Buyers (Bids)

No. Vol. Price($)
2 146314 7.6¢
 

Sellers (Offers)

Price($) Vol. No.
8.3¢ 106165 2
View Market Depth
Last trade - 16.10pm 09/05/2024 (20 minute delay) ?
Last
7.7¢ 		  Change
-0.004 ( 3.75 %)
Open High Low Volume
7.9¢ 8.0¢ 7.7¢ 79316
Last updated 15.57pm 09/05/2024 ?

Top Stories

UNITH's digital humans expand into Amazon; Facebook

AI-powered 'Digital Human' chatbot developer UNITH has announced its in-house tech can now harmonise with that used by Facebook and Amazon.
CBA profits fall 3% in March quarter but funding portfolio is flourishing Commonwealth Bank has reported a 3 percent fall in profits for the March quarter of 2024, compared to the previous quarter.
Raiden opens door to private Mallina in win-win Arrow Gold divestment Raiden Resources has announced its execution of a farm-in deal on-site Raiden's non-core asset, the Arrow gold project.
Prominence impresses the market with uranium grading 5,269ppm in Kazakhstan Prominence Energy has seen shares rise 33% on news of uranium grading up to 5,269ppm from early sampling work in Kazakhstan.
Recce breathes better on positive lung infection drug pilot test results Recce Pharmaceuticals Ltd has revealed positive results from its pilot test on synthetic drug Recce 327, which aims to treat lung infections.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.